Label: VASOPRESSIN injection, solution

  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated January 23, 2017

If you are a consumer or patient please visit this version.


    Vasopressin Injection, USP is a sterile solution of synthetic vasopressin of the posterior pituitary gland for intramuscular (IM) or subcutaneous use. It is substantially free from the oxytocic principle and is standardized to contain 20 pressor units/mL. The chemical name is Vasopressin, 8-L-arginine and has the following structural formula:


    Each mL contains:  20 USP Vasopressin Units, chlorobutanol (anhydrous) 5 mg as preservative; Water for Injection q.s. Glacial acetic acid and/or sodium hydroxide may have been added for pH adjustment (2.4-4.5).


    The antidiuretic action of vasopressin is ascribed to increasing reabsorption of water by the renal tubules.

    Vasopressin can cause contraction of smooth muscle of the gastrointestinal tract and of all parts of the vascular bed, especially the capillaries, small arterioles and venules with less effect on the smooth musculature of the large veins. The direct effect on the contractile elements is neither antagonized by adrenergic blocking agents nor prevented by vascular denervation. 

    Following subcutaneous or intramuscular administration of vasopressin injection, the duration of antidiuretic activity is variable but effects are usually maintained for 2 to 8 hours. 

    The majority of a dose of vasopressin is metabolized and rapidly destroyed in the liver and kidneys. Vasopressin has a plasma half-life of about 10 to 20 minutes. Approximately 5% of a subcutaneous dose of vasopressin is excreted in urine unchanged after 4 hours.


    Vasopressin Injection, USP is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus.


    Anaphylaxis or hypersensitivity to the drug or its components.


    This drug should not be used in patients with vascular disease, especially disease of the coronary arteries, except with extreme caution. In such patients, even small doses may precipitate anginal pain, and with larger doses, the possibility of myocardial infarction should be considered. 

    Vasopressin may produce water intoxication. The early signs of drowsiness, listlessness and headaches should be recognized to prevent terminal coma and convulsions.



    Vasopressin should be used cautiously in the presence of epilepsy, migraine, asthma, heart failure or any state in which a rapid addition to extracellular water may produce hazard for an already overburdened system.

    Chronic nephritis with nitrogen retention contraindicates the use of vasopressin until reasonable nitrogen blood levels have been attained.

    Information for Patients

    Side effects such as blanching of skin, abdominal cramps, and nausea may be reduced by taking 1 or 2 glasses of water at the time of vasopressin administration. These side effects are usually not serious and probably will disappear within a few minutes.

    Laboratory Tests

    Electrocardiograms (ECG) and fluid and electrolyte status determinations are recommended at periodic intervals during therapy.

    Drug Interactions

    The following drugs may potentiate the antidiuretic effect of vasopressin when used concurrently:  carbamazepine; chlorpropamide; clofibrate; urea; fludrocortisone; tricyclic antidepressants. 

    The following drugs may decrease the antidiuretic effect of vasopressin when used concurrently:  demeclocycline; norepinephrine; lithium; heparin; alcohol.

    Ganglionic blocking agents may produce a marked increase in sensitivity to the pressor effects of vasopressin.

    Pregnancy Category C

    Animal reproduction studies have not been conducted with vasopressin. It is also not known whether vasopressin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Vasopressin should be given to a pregnant woman only if clearly needed.

    Labor and Delivery

    Doses of vasopressin sufficient for an antidiuretic effect are not likely to produce tonic uterine contractions that could be deleterious to the fetus or threaten the continuation of the pregnancy.

    Nursing Mothers

    Caution should be exercised when vasopressin is administered to a nursing woman.


    Local or systemic allergic reactions may occur in hypersensitive individuals. The following side effects have been reported following the administration of vasopressin:

    Body as a Whole

    Anaphylaxis (cardiac arrest and/or shock) has been observed shortly after injection of vasopressin.


    Cardiac arrest, circumoral pallor, arrhythmias, decreased cardiac output, angina, myocardial ischemia, peripheral vasoconstriction, and gangrene.


    Abdominal cramps, nausea, vomiting, passage of gas.

    Nervous System

    Tremor, vertigo, "pounding" in head.


    Bronchial constriction.

    Skin and Appendages

    Sweating, urticaria, cutaneous gangrene.


    Water intoxication may be treated with water restriction and temporary withdrawal of vasopressin until polyuria occurs. Severe water intoxication may require osmotic diuresis with mannitol, hypertonic dextrose, or urea alone or with furosemide.


    Vasopressin Injection may be administered IM or subcutaneously.

    Ten units (0.5 mL) of Vasopressin Injection will usually elicit full physiologic response in adult patients; 5 units (0.25 mL) will be adequate in many cases. Vasopressin Injection should be given IM at three or four hour intervals as needed. The dosage should be proportionately reduced for pediatric patients. (For an additional discussion of dosage, consult the sections below.)

    When determining the dose of Vasopressin Injection for a given case, the following should be kept in mind:

    It is particularly desirable to give a dose not much larger than is just sufficient to elicit the desired physiologic response. Excessive doses may cause undesirable side effects-blanching of the skin, abdominal cramps, nausea-which, though not serious, may be alarming to the patient. Spontaneous recovery from such side effects occurs in a few minutes. It has been found that one or two glasses of water given at the time Vasopressin Injection is administered reduces such symptoms.

    Abdominal Distention

    In the average postoperative adult patient, give 5 units (0.25 mL) initially, increase to 10 units (0.5 mL) at subsequent injections if necessary. It is recommended that Vasopressin Injection be given IM and that injections be repeated at three or four hour intervals as required. Dosage to be reduced proportionately for pediatric patients.

    Vasopressin Injection used in this manner will frequently prevent, or relieve, postoperative distention. These recommendations apply also to distention complicating pneumonia or other acute toxemias.

    Abdominal Roentgenography

    For the average case, two injections of 10 units (0.5 mL) each are suggested. These should be given two hours and one-half hour, respectively, before films are exposed. Many roentgenologists advise giving an enema prior to the first dose of Vasopressin Injection.

    Diabetes Insipidus

    Vasopressin Injection may be given by injection or administered intranasally on cotton pledgets, by nasal spray, or by dropper. The dose by injection is 5 to 10 units (0.25 to 0.5 mL) repeated two or three times daily as needed. When Vasopressin Injection is administered intranasally by spray or on pledgets, the dosage and interval between treatments must be determined for each patient.

    Parenteral drug products should be inspected visually for paticulate matter and discoloration prior to administration, whenever solution and container permit.


    Product No.NDC No.
    3020163323-302-01Vasopressin Injection, USP 20 units, 1 mL in a 2 mL flip-top vial in packages of 25.

    Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

    Do not freeze.

    Vial stoppers do not contain natural rubber latex.



    Schaumburg, IL 60173


    Revised:  March 2010



    vasopressin injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:52584-302(NDC:63323-302)
    Route of AdministrationINTRAMUSCULAR, SUBCUTANEOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Inactive Ingredients
    Ingredient NameStrength
    ACETIC ACID (UNII: Q40Q9N063P)  
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:52584-302-011 in 1 BAG12/17/201301/16/2017
    11 mL in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    unapproved drug other12/17/2013
    Labeler - Feneral Injectables & Vaccines, Inc (108250663)